CN109053550A - 一种苯并吲哚衍生物的合成方法 - Google Patents

一种苯并吲哚衍生物的合成方法 Download PDF

Info

Publication number
CN109053550A
CN109053550A CN201811088822.4A CN201811088822A CN109053550A CN 109053550 A CN109053550 A CN 109053550A CN 201811088822 A CN201811088822 A CN 201811088822A CN 109053550 A CN109053550 A CN 109053550A
Authority
CN
China
Prior art keywords
synthetic method
benzindole
catalyst
naphthylamines
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201811088822.4A
Other languages
English (en)
Other versions
CN109053550B (zh
Inventor
张金
汪小钢
杨秀芳
马养民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shaanxi Yuanzhijin Biotechnology Co.,Ltd.
Original Assignee
Shaanxi University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaanxi University of Science and Technology filed Critical Shaanxi University of Science and Technology
Priority to CN201811088822.4A priority Critical patent/CN109053550B/zh
Publication of CN109053550A publication Critical patent/CN109053550A/zh
Application granted granted Critical
Publication of CN109053550B publication Critical patent/CN109053550B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/90Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)

Abstract

本发明公开了一种苯并吲哚衍生物的合成方法,向溶剂中加入萘胺和重氮化合物,以及催化剂和添加剂,然后进行C‑H键活化环化后分离提纯即得到苯并吲哚。本发明的合成方法首次在导向基团导向重氮卡宾插入反应中使用了钌催化剂,并且条件温和,不需要惰性气体保护,溶剂绿色环保,有较强的底物适用性以及良好的产率。

Description

一种苯并吲哚衍生物的合成方法
技术领域
本发明属于有机合成领域,具体涉及一种苯并吲哚衍生物的合成方法。
背景技术
苯并吲哚化合物是有机化学中一类重要的稠杂环骨架,在发光材料、医药等方面有着重要的前景。传统的苯并吲哚化合物的构成方法是用萘胺与烯烃通过C-H键活化环化而成[Wang,X.W.;Li,X.T.;Xiao,J.;Jiang,Y.;Li,X.W.synlett2012,23,1649.],但是这类方法往往需要苛刻的反应条件,如需要在惰性气体保护下反应,并且使用的催化剂比较单一。
发明内容
本发明的目的在于提供一种苯并吲哚衍生物的合成方法,以克服上述现有技术存在的缺陷,本发明以萘胺和重氮酯为反应原料,在溶剂的存在下,加入催化剂和添加剂,在较为温和的反应条件下高效合成苯并吲哚。
为达到上述目的,本发明采用如下技术方案:
一种苯并吲哚衍生物的合成方法,向溶剂中加入如式1所示的萘胺和如式2所示的重氮酯,以及催化剂和添加剂,然后进行C-H键活化官能团化环化反应后分离提纯即得到如式3所示的苯并吲哚类衍生物;
其中,R1选自氢、烷基、取代苯基或Boc;R2选自氢、卤素、氨基、烷基、烷氧基或取代苯基;R3选自甲基、乙基、异丙基、正丙基、叔丁基或苯基;R4选自甲氧酰基、乙氧酰基、叔丁氧酰基、苄氧酰基或苯氧酰基。
进一步地,所述的萘胺和重氮酯的摩尔比为1.0:1.2。
进一步地,所述的萘胺、催化剂和添加剂的摩尔比为100:5:25。
进一步地,所述的C-H键活化官能团化环化反应具体为:在65℃温度下加热搅拌16h。
进一步地,所述的催化剂为甲基异丙基苯二氯化钌二聚体。
进一步地,所述的添加剂为醋酸铯。
进一步地,所述的溶剂为乙醇和水的混合溶液。
进一步地,向溶剂中加入如式1所示的萘胺和如式2所示的重氮酯以及催化剂和添加剂后,萘胺在溶剂中的浓度为0.043摩尔/升。
与现有技术相比,本发明具有以下有益的技术效果:
本发明采用萘胺和重氮酯合成苯并吲哚类衍生物,反应过程中不涉及氧化还原步骤,并且原料比较稳定,不容易被氧化,因此反应条件温和,不需要在惰性气体保护等苛刻的条件下即可进行反应,另外本发明采用的溶剂绿色环保,有较强的底物适用性,且产物易于分离,产率较高。
附图说明
图1为实施例1所制备的产物的1H NMR谱图;
图2为实施例1所制备的产物的13C NMR谱图;
图3为实施例2所制备的产物的1H NMR谱图;
图4为实施例2所制备的产物的13C NMR谱图;
图5为实施例3所制备的产物的1H NMR谱图;
图6为实施例3所制备的产物的13C NMR谱图;
图7为实施例4所制备的产物的1H NMR谱图;
图8为实施例4所制备的产物的13C NMR谱图;
图9为实施例5所制备的产物的1H NMR谱图;
图10为实施例5所制备的产物的13C NMR谱图;
图11为实施例6所制备的产物的1H NMR谱图;
图12为实施例6所制备的产物的13C NMR谱图;
图13为实施例7所制备的产物的1H NMR谱图;
图14为实施例7所制备的产物的13C NMR谱图;
图15为实施例8所制备的产物的1H NMR谱图;
图16为实施例8所制备的产物的13C NMR谱图;
图17为实施例9所制备的产物的1H NMR谱图;
图18为实施例9所制备的产物的13C NMR谱图;
图19为实施例10所制备的产物的1H NMR谱图;
图20为实施例10所制备的产物的13C NMR谱图;
图21为实施例11所制备的产物的1H NMR谱图;
图22为实施例11所制备的产物的13C NMR谱图;
图23为实施例12所制备的产物的1H NMR谱图;
图24为实施例12所制备的产物的13C NMR谱图;
图25为实施例13所制备的产物的1H NMR谱图;
图26为实施例13所制备的产物的13C NMR谱图;
图27为实施例14所制备的产物的1H NMR谱图;
图28为实施例14所制备的产物的13C NMR谱图;
图29为实施例15所制备的产物的1H NMR谱图;
图30为实施例15所制备的产物的13C NMR谱图;
图31为实施例16所制备的产物的1H NMR谱图;
图32为实施例16所制备的产物的13C NMR谱图;
图33为实施例17所制备的产物的1H NMR谱图;
图34为实施例17所制备的产物的13C NMR谱图;
图35为实施例18所制备的产物的1H NMR谱图;
图36为实施例18所制备的产物的13C NMR谱图;
图37为实施例19所制备的产物的1H NMR谱图;
图38为实施例19所制备的产物的13C NMR谱图;
图39为实施例20所制备的产物的1H NMR谱图;
图40为实施例20所制备的产物的13C NMR谱图。
具体实施方式
下面对本发明的实施方式做进一步详细描述:
一种苯并吲哚衍生物的合成方法,向溶剂中加入如式1所示的萘胺和如式2所示的重氮酯,以及催化剂和添加剂,所述的萘胺和重氮酯的摩尔比为1.0:1.2,且萘胺、催化剂和添加剂的摩尔比为100:5:25,萘胺在溶剂中的浓度为0.043摩尔/升,然后在65℃温度下加热搅拌16h后分离提纯即得到如式3所示的苯并吲哚类衍生物,反应过程中条件温和,不需要惰性气体的保护。
其中,R1选自氢、烷基、取代苯基、Boc;R2选自氢、卤素、氨基、烷基、烷氧基或取代苯基;R3选自甲基、乙基、异丙基、正丙基、叔丁基或苯基;R4选自甲氧酰基、乙氧酰基、叔丁氧酰基、苄氧酰基、或苯氧酰基;催化剂为甲基异丙基苯二氯化钌二聚体;添加剂为醋酸铯;溶剂为水和乙醇的混合溶液。
下面结合实施例对本发明做进一步详细描述:
实施例1
Ethyl 2-acetyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到19.2mg黄色油状化合物,产率为76%,所得产品结构式如下:
如图1和图2所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.91(s,1H),8.24(d,J=8.2Hz,1H),7.92(d,J=8.1Hz,1H),7.73(t,J=7.5Hz,1H),7.62(t,J=7.6Hz,1H),7.37(d,J=8.6Hz,1H),7.21(d,J=8.6Hz,1H),4.10(qq,J=7.1,3.8Hz,2H),1.55(s,3H),1.11(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.88,168.60,162.54,137.91,130.65,128.57,126.08,123.49,120.56,119.98,118.42,111.31,70.05,61.48,19.98,13.89.
实施例2
Ethyl 2-acetyl-6-bromo-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-溴-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到19.5mg黄色油状化合物,产率为59%,所得产品结构式如下:
如图3和图4所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=9.20(s,1H),8.32(d,J=7.7Hz,1H),8.15(d,J=8.3Hz,1H),7.92(t,J=8.3Hz,1H),7.75(t,J=8.1Hz,1H),7.69(s,1H),4.11(qq,J=7.2,3.8Hz,2H),1.56(s,3H),1.11(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=194.52,168.15,161.82,134.95,132.22,127.58,127.25,124.18,123.53,121.58,111.77,110.26,70.29,61.64,19.80,13.86.
实施例3
Ethyl 2-acetyl-6-amino-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-氨基-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到17.7mg黄色油状化合物,产率为47%,所得产品结构式如下:
如图5和图6所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.62(s,1H),7.37(dd,J=8.3,5.5Hz,2H),7.28(t,J=7.8Hz,1H),7.20(s,1H),6.91–6.88(m,1H),5.85(s,2H),4.08(qt,J=7.1,3.8Hz,2H),1.51(s,3H),1.10(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.17,169.49,158.42,140.85,124.07,116.92,112.24,108.08,104.66,101.09,69.56,61.13,20.38,13.95.
实施例4
Ethyl 2-acetyl-6-phenyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-苯基-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到19.1mg黄色油状化合物,产率为58%,所得产品结构式如下:
如图7和图8所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=9.04(s,1H),8.34(d,J=7.8Hz,1H),7.78(d,J=8.0Hz,1H),7.75–7.70(m,1H),7.70–7.65(m,1H),7.53–7.48(m,2H),7.44(d,J=6.7Hz,3H),7.23(s,1H),4.13(q,J=7.0Hz,2H),1.59(s,3H),1.14(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.89,168.56,161.95,139.68,136.06,130.89,130.27,129.76,128.51,127.18,126.47,126.16,123.95,120.81,120.13,110.81,70.15,61.54,20.03,13.93.
实施例5
Ethyl 2-acetyl-6-(4-methoxyphenyl)-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-(对甲氧基苯基)-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到23.0mg黄色油状化合物,产率为64%,所得产品结构式如下:
如图9和图10所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.99(s,1H),8.33(d,J=7.9Hz,1H),7.78(d,J=8.1Hz,1H),7.74–7.69(m,1H),7.68–7.63(m,1H),7.36(d,J=8.6Hz,2H),7.19(s,1H),7.06(d,J=8.6Hz,2H),4.12(q,J=7.0Hz,2H),3.83(s,3H),1.58(s,3H),1.13(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.95,168.59,161.83,158.48,136.36,131.87,130.84,130.76,130.03,126.56,126.06,123.94,120.87,119.91,113.96,110.88,70.13,61.50,55.13,20.03,13.92.
实施例6
Ethyl 2-acetyl-6-(p-tolyl)-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-(对甲基苯基)-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到20.1mg黄色油状化合物,产率为61%,所得产品结构式如下:
如图11和图12所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.99(s,1H),8.33(d,J=7.8Hz,1H),7.78(d,J=7.9Hz,1H),7.74–7.63(m,2H),7.32(s,4H),7.20(s,1H),4.12(qd,J=7.1,1.2Hz,2H),2.40(s,3H),1.58(s,3H),1.13(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.91,168.58,161.88,136.75,136.37,136.20,130.79,130.27,129.62,129.09,126.54,126.10,123.92,120.84,119.94,110.86,70.13,61.52,20.75,20.03,13.93.
实施例7
Ethyl 2-acetyl-6-(4-isopropylphenyl)-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-(对异丙基苯基)-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到24.1mg黄色油状化合物,产率为65%,所得产品结构式如下:
如图13和图14所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=9.00(s,1H),8.33(d,J=7.5Hz,1H),7.80(d,J=8.2Hz,1H),7.75–7.70(m,1H),7.69–7.64(m,1H),7.37(d,J=1.7Hz,4H),7.21(s,1H),4.13(q,J=6.9Hz,2H),2.98(p,J=6.9Hz,1H),1.58(s,3H),1.28(d,J=6.9Hz,6H),1.13(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.90,168.58,161.88,147.22,137.10,136.16,130.84,130.26,129.68,126.56,126.43,126.12,123.92,120.82,119.96,110.86,70.12,61.53,33.13,23.87,20.03,13.93.
实施例8
Ethyl 2-acetyl-6-(4-(tert-butyl)phenyl)-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-(对叔丁基苯基)-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到23.5mg黄色油状化合物,产率为61%,所得产品结构式如下:
如图15和图16所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=9.03(s,1H),8.33(d,J=8.0Hz,1H),7.80(d,J=8.4Hz,1H),7.76–7.70(m,1H),7.69–7.64(m,1H),7.53(d,J=8.3Hz,2H),7.38(d,J=8.2Hz,2H),7.21(s,1H),4.12(q,J=7.0Hz,2H),1.58(s,3H),1.36(s,9H),1.13(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.88,168.58,161.88,149.47,136.73,136.15,130.84,130.17,129.43,126.57,126.11,125.27,123.92,120.83,119.96,110.87,70.12,61.52,34.30,31.16,20.04,13.93.
实施例9
Ethyl 2-acetyl-6-(3,5-dimethylphenyl)-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-(3,5-二甲基苯基)-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到22.8mg黄色油状化合物,产率为64%,所得产品结构式如下:
如图17和图18所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.99(s,1H),8.33(d,J=7.9Hz,1H),7.80(d,J=8.0Hz,1H),7.74–7.69(m,1H),7.68–7.63(m,1H),7.19(s,1H),7.07–7.02(m,3H),4.13(qd,J=7.0,2.0Hz,2H),2.34(s,6H),1.58(s,3H),1.13(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.92,168.59,161.87,139.58,137.46,136.12,130.81,130.52,128.59,127.52,126.62,126.07,123.90,120.78,119.88,110.81,70.12,61.52,20.93,20.01,13.92.
实施例10
Ethyl 2-acetyl-6-(naphthalen-2-yl)-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的4-萘基-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到14.9mg黄色油状化合物,产率为39%,所得产品结构式如下:
如图19和图20所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=9.08(s,1H),8.39–8.35(m,1H),8.06–7.97(m,4H),7.86–7.82(m,1H),7.71(dddd,J=16.6,8.3,7.0,1.5Hz,2H),7.62–7.55(m,3H),7.36(s,1H),4.14(qd,J=7.0,1.6Hz,2H),1.60(s,3H),1.14(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.90,168.56,162.02,137.31,136.16,133.16,132.04,130.97,130.11,128.26,128.21,127.92,127.72,127.54,126.57,126.34,126.21,126.08,124.00,120.85,120.62,110.93,99.49,70.19,61.55,20.02,13.94.
实施例11
Ethyl 2-acetyl-1-methyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的N-甲基-1-萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到14.9mg黄色油状化合物,产率为56%,所得产品结构式如下:
如图21和图22所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.63(dd,J=8.6,1.0Hz,1H),7.92(d,J=7.9Hz,1H),7.75–7.67(m,1H),7.56(ddd,J=8.4,7.0,1.3Hz,1H),7.37(d,J=8.5Hz,1H),7.20(d,J=8.5Hz,1H),4.22–4.02(m,2H),3.55(s,3H),1.57(s,3H),1.12(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=194.12,167.56,161.32,140.07,130.64,129.60,126.53,126.30,121.97,120.35,119.12,113.48,76.52,62.26,34.62,18.25,14.45.
实施例12
Ethyl 1-acetyl-2,4-dihydro-1H-pyrrolo[2,3,4-c,d]indole-1-carboxylate的制备
将0.1mmol的4-氨基吲哚溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到17.8mg黄色油状化合物,产率为74%,所得产品结构式如下:
如图23和图24所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=11.61(s,1H),8.18(s,1H),7.32–7.27(m,1H),7.08(d,J=8.6Hz,1H),6.83(d,J=8.6Hz,1H),6.66–6.61(m,1H),4.07(qq,J=6.9,3.8Hz,2H),1.47(s,3H),1.11(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=195.17,169.49,158.42,140.85,124.07,116.92,112.24,108.08,104.66,101.09,69.56,61.13,20.38,13.95.
实施例13
Methyl 2-acetyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸甲酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到17.8mg黄色油状化合物,产率为79%,所得产品结构式如下:
如图25和图26所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.92(s,1H),8.23(d,J=8.2Hz,1H),7.92(d,J=8.1Hz,1H),7.77–7.70(m,1H),7.65–7.59(m,1H),7.37(d,J=8.6Hz,1H),7.22(d,J=8.6Hz,1H),3.63(s,3H),1.56(s,3H);13C NMR(101MHz,CDCl3)δ=195.79,169.12,162.55,137.93,130.67,128.57,126.09,123.47,120.58,119.94,118.52,111.38,69.97,52.76,19.94.
实施例14
Benzyl 2-acetyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备:
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸卞酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到23.3mg黄色油状化合物,产率为74%,所得产品结构式如下:
如图27和图28所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.96(s,1H),8.24(d,J=8.1Hz,1H),7.92(d,J=8.1Hz,1H),7.75–7.70(m,1H),7.64–7.59(m,1H),7.37(d,J=8.6Hz,1H),7.34–7.23(m,5H),7.21(d,J=8.6Hz,1H),5.18(dd,J=18.2,5.3Hz,2H),1.59(s,3H);13C NMR(101MHz,CDCl3)δ=195.69,168.49,162.56,137.93,135.73,130.65,128.58,128.33,127.91,127.17,126.09,123.46,120.58,119.94,118.51,111.39,70.13,66.43,19.93.
实施例15
Tert-butyl 2-acetyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备:
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基乙酰乙酸叔丁酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到19.1mg黄色油状化合物,产率为68%,所得产品结构式如下:
如图29和图30所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.87(s,1H),8.26(d,J=8.2Hz,1H),7.91(d,J=8.1Hz,1H),7.75–7.69(m,1H),7.64–7.58(m,1H),7.36(d,J=8.6Hz,1H),7.19(d,J=8.5Hz,1H),1.50(s,3H),1.34(s,9H);13C NMR(101MHz,CDCl3)δ=196.07,167.51,162.45,137.85,130.48,128.51,125.95,123.49,120.59,120.00,118.16,111.35,81.54,70.85,27.40,19.94.
实施例16
Ethyl 2-propionyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备:
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基丙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到19.7mg黄色油状化合物,产率为74%,所得产品结构式如下:
如图31和图32所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.87(s,1H),8.37(d,J=8.2Hz,1H),7.91(d,J=8.2Hz,1H),7.73(t,J=7.5Hz,1H),7.62(t,J=7.6Hz,1H),7.34(d,J=8.5Hz,1H),7.19(d,J=8.6Hz,1H),4.12(p,J=6.9Hz,2H),2.16(dq,J=14.7,7.4Hz,1H),1.96(dt,J=13.9,7.1Hz,1H),1.13(t,J=7.1Hz,3H),0.83(t,J=7.3Hz,3H);13C NMR(101MHz,CDCl3)δ=194.63,167.91,163.13,137.92,130.61,128.54,126.01,123.70,120.53,119.74,118.23,112.15,74.57,61.44,27.39,13.93,7.79.
实施例17
Ethyl 2-butyryl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备:
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基正丙酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到19.3mg黄色油状化合物,产率为69%,所得产品结构式如下:
如图33和图34所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.90(s,1H),8.36(d,J=8.2Hz,1H),7.91(d,J=8.1Hz,1H),7.76–7.71(m,1H),7.65–7.59(m,1H),7.34(d,J=8.6Hz,1H),7.18(d,J=8.6Hz,1H),4.16–4.07(m,2H),2.15–1.84(m,3H),1.12(t,J=7.1Hz,3H),0.86(t,J=7.3Hz,4H);13C NMR(101MHz,CDCl3)δ=194.61,167.93,163.00,137.91,130.60,128.53,125.99,123.71,120.52,119.75,118.22,111.99,74.16,61.44,36.36,16.53,13.93.
实施例18
Ethyl 2-isobutyryl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备:
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基异丙乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到18.2mg黄色油状化合物,产率为65%,所得产品结构式如下:
如图35和图36所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.75(s,1H),8.54(d,J=8.1Hz,1H),7.91(d,J=8.1Hz,1H),7.76–7.70(m,1H),7.65–7.60(m,1H),7.32(d,J=8.6Hz,1H),7.17(d,J=8.6Hz,1H),4.20–4.09(m,2H),2.72(p,J=6.8Hz,1H),1.16(t,J=7.1Hz,3H),1.09(d,J=6.8Hz,3H),0.63(d,J=6.7Hz,3H);13C NMR(101MHz,CDCl3)δ=193.62,167.44,163.71,137.88,130.58,128.49,125.93,124.08,120.62,119.60,118.21,112.37,78.75,61.54,33.54,17.99,15.35,13.96.
实施例19
Ethyl 2-pivaloyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备:
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基叔丁酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到13.5mg黄色油状化合物,产率为46%,所得产品结构式如下:
如图37和图38所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=8.65(s,1H),8.62(d,J=7.7Hz,1H),7.88(d,J=7.8Hz,1H),7.74–7.67(m,1H),7.59(td,J=7.6,7.0,1.2Hz,1H),7.32(d,J=8.5Hz,1H),7.15(d,J=8.5Hz,1H),4.18–4.08(m,2H),1.15(t,J=7.1Hz,3H),1.11(s,9H);13C NMR(101MHz,CDCl3)δ=194.26,167.46,162.40,138.31,130.87,128.92,126.28,124.72,120.91,120.03,118.46,113.74,78.28,61.72,40.57,27.94,25.55,14.48.
实施例20
Ethyl 2-benzoyl-1,2-dihydrobenzo[c,d]indole-2-carboxylate的制备:
将0.1mmol的萘胺溶于2mL H2O的史莱克管中,加入0.2mmol重氮基苯酰乙酸乙酯,加入0.3mL良溶剂乙醇促进溶解,以0.005mmol[RuCl2(p-cymene)]2为催化剂,0.025mmol醋酸铯为添加剂,于65℃下加热搅拌16小时,用TLC监测反应的进行,反应完全后用5mL二氯甲烷萃取三次,合并有机相进行浓缩,经硅胶柱层析分离,得到26.4mg黄色固体化合物,产率为84%,所得产品结构式如下:
如图39和图40所示,产品核磁表征:1H NMR(400MHz,CDCl3)δ=9.55(s,1H),8.53(d,J=8.1Hz,1H),7.93(d,J=8.1Hz,1H),7.78–7.73(m,1H),7.70–7.63(m,3H),7.44–7.33(m,4H),7.22(d,J=8.6Hz,1H),4.18(q,J=7.1Hz,2H),1.14(t,J=7.1Hz,3H);13C NMR(101MHz,CDCl3)δ=192.61,167.49,162.32,138.04,135.33,130.81,128.59,128.16,126.47,126.17,123.88,120.38,119.97,118.72,110.76,75.15,62.03,13.86。

Claims (8)

1.一种苯并吲哚衍生物的合成方法,其特征在于,向溶剂中加入如式1所示的萘胺和如式2所示的重氮酯,以及催化剂和添加剂,然后进行C-H键活化官能团化环化反应后分离提纯即得到如式3所示的苯并吲哚类衍生物;
其中,R1选自氢、烷基、取代苯基或Boc;R2选自氢、卤素、氨基、烷基、烷氧基或取代苯基;R3选自甲基、乙基、异丙基、正丙基、叔丁基或苯基;R4选自甲氧酰基、乙氧酰基、叔丁氧酰基、苄氧酰基或苯氧酰基。
2.根据权利要求1所述的一种苯并吲哚衍生物的合成方法,其特征在于,所述的萘胺和重氮酯的摩尔比为1.0:1.2。
3.根据权利要求1所述的一种苯并吲哚衍生物的合成方法,其特征在于,所述的萘胺、催化剂和添加剂的摩尔比为100:5:25。
4.根据权利要求1所述的一种苯并吲哚衍生物的合成方法,其特征在于,所述的C-H键活化官能团化环化反应具体为:在65℃温度下加热搅拌16h。
5.根据权利要求1所述的一种苯并吲哚衍生物的合成方法,其特征在于,所述的催化剂为甲基异丙基苯二氯化钌二聚体。
6.根据权利要求1所述的一种苯并吲哚衍生物的合成方法,其特征在于,所述的添加剂为醋酸铯。
7.根据权利要求1所述的一种苯并吲哚衍生物的合成方法,其特征在于,所述的溶剂为乙醇和水的混合溶液。
8.根据权利要求1所述的一种苯并吲哚衍生物的合成方法,其特征在于,向溶剂中加入如式1所示的萘胺和如式2所示的重氮酯以及催化剂和添加剂后,萘胺在溶剂中的浓度为0.043摩尔/升。
CN201811088822.4A 2018-09-18 2018-09-18 一种苯并吲哚衍生物的合成方法 Active CN109053550B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811088822.4A CN109053550B (zh) 2018-09-18 2018-09-18 一种苯并吲哚衍生物的合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811088822.4A CN109053550B (zh) 2018-09-18 2018-09-18 一种苯并吲哚衍生物的合成方法

Publications (2)

Publication Number Publication Date
CN109053550A true CN109053550A (zh) 2018-12-21
CN109053550B CN109053550B (zh) 2021-06-25

Family

ID=64762079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811088822.4A Active CN109053550B (zh) 2018-09-18 2018-09-18 一种苯并吲哚衍生物的合成方法

Country Status (1)

Country Link
CN (1) CN109053550B (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108329256A (zh) * 2018-01-18 2018-07-27 嘉兴学院 一种多取代含硫或硒的苯并[c,d]吲哚类化合物的合成方法
CN110627721A (zh) * 2019-10-29 2019-12-31 陕西科技大学 一种菲啶类化合物及其合成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108329256A (zh) * 2018-01-18 2018-07-27 嘉兴学院 一种多取代含硫或硒的苯并[c,d]吲哚类化合物的合成方法
CN110627721A (zh) * 2019-10-29 2019-12-31 陕西科技大学 一种菲啶类化合物及其合成方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIAN YANG ET AL.: "Enantioselective Synthesis of 2,2,3-Trisubstituted Indolines via Bimetallic Relay Catalysis of α‑Diazoketones with Enones", 《ORG. LETT.》 *
SOURAV PRADHAN ET AL.: "Oxidative C−H/N−H Annulation of Aromatic Amides with Dialkyl Malonates: Access to Isoindolinones and Dihydrobenzoindoles", 《J. ORG. CHEM.》 *
XIAOWEI WANG ET AL.: "Rhodium(III)-Catalyzed Oxidative Olefination of N-(Naphthalen-1-yl)amides", 《SYNLETT》 *
张珍辉: "铑(Ⅲ)-催化吲哚导向卡宾体插入芳基C-H键/环化反应研究", 《中国优秀硕士学位论文全文数据库 工程科技I辑》 *

Also Published As

Publication number Publication date
CN109053550B (zh) 2021-06-25

Similar Documents

Publication Publication Date Title
Liu et al. One-pot three-component synthesis of pyrazoles through a tandem coupling-cyclocondensation sequence
Zhang et al. Phosphine-catalyzed highly diastereoselective [3+ 2] cyclization of isatin derived electron-deficient alkenes with α-allenic esters
CN111675712B (zh) 一种吡唑啉酮并苯二氮杂卓类化合物的合成方法
Xu et al. A novel approach to 1-monosubstituted 1, 2, 3-triazoles by a click cycloaddition/decarboxylation process
CN111217736B (zh) 一种光催化下2-酰基吲哚化合物的合成方法
Zheng et al. PtI 2-Catalyzed tandem 3, 3-rearrangement/Nazarov reaction of arylpropargylic esters: synthesis of indanone derivatives
Beccalli et al. Uncommon intramolecular palladium-catalyzed cyclization of indole derivatives
Kusurkar et al. Efficient one-pot synthesis of anti-HIV and anti-tumour β-carbolines
Saunthwal et al. Regioselective preferential CH activation of sterically hindered 1, 3-dienes over [4+ 2] cycloaddition
Yasuhara et al. Synthesis of 2, 3-disubstituted indole using palladium (II)-catalyzed cyclization with alkenylation reaction
CN110437124B (zh) 一种吲哚醌衍生物的制备方法
Guin et al. 1, 6-Aza-Michael addition of para-quinone methides with N-heterocycles catalyzed by Zn (OTf) 2: A regioselective approach to N-diarylmethyl-substituted heterocycles
CN111020622B (zh) 一种含C(sp2)-Br键化合物的制备方法
Zhu et al. Synthesis of isoquinolone via rhodium (III)-catalyzed CH activation with 1, 4, 2-dioxazol-5-ones as oxidizing directing group
CN106117216B (zh) 一种常压合成6H-异吲哚[2,1-a]吲哚-6-酮类化合物的方法
Ren et al. Three-component reaction of N′-(2-alkynylbenzylidene) hydrazide, α, β-unsaturated carbonyl compound, with bromine
Wagger et al. Synthesis of (S, Z)-3-[(1H-indol-3-yl) methylidene] hexahydropyrrolo [1, 2-a] pyrazin-4 (1H)-one: an alternative, enaminone based, route to unsaturated cyclodipeptides
Yanai et al. Preparation of phenanthridines from N-(o-arylbenzyl) trifluoromethanesulfonamides with 1, 3-diiodo-5, 5-dimethylhydantoin
Cherry et al. Regioselective synthesis of 5-alkylidene and 5-(iodoalkylidene)-pyrrol-2 (5H)-ones by halolactamisation of (2Z, 4E)-dienamides and (Z)-alk-2-en-4-ynamides
Maruyama et al. Novel synthesis of fused indoles and 2-substituted indoles by the palladium-catalyzed cyclization of N-cycloalkenyl-o-haloanilines
CN109053550A (zh) 一种苯并吲哚衍生物的合成方法
Revial et al. Enantioselective synthesis of (+)-α-vetivone through the Michael reaction of chiral imines
Chernyak et al. Cascade carbopalladation-annulation approach toward polycylic derivatives of indole and indolizine
Shimizu et al. Total synthesis of (±)-erythrocarine using dienyne metathesis
CN113912609B (zh) 一种天然生物碱色胺酮及其衍生物的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230328

Address after: 710000 2-2-2, Building 6, Science and Technology Enterprise Park, No. 2 West Qinling Avenue, Caotang Science and Technology Industrial Base, High-tech Zone, Xi'an, Shaanxi Province

Patentee after: Shaanxi Yuanzhijin Biotechnology Co.,Ltd.

Address before: No. 1, Weiyang District university garden, Xi'an, Shaanxi Province, Shaanxi

Patentee before: SHAANXI University OF SCIENCE & TECHNOLOGY